Cabaletta Bio, Inc.

NasdaqGS:CABA Stok Raporu

Piyasa değeri: US$533.2m

Cabaletta Bio Yönetim

Yönetim kriter kontrolleri 4/4

Cabaletta Bio CEO'su Steven Nichtberger, Jan2017 tarihinde atandı, in görev süresi 9.33 yıldır. in toplam yıllık tazminatı $ 2.40M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27.5% maaş ve 72.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.86% ine doğrudan sahiptir ve bu hisseler $ 4.56M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 6.3 yıldır.

Anahtar bilgiler

Steven Nichtberger

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi27.46%
CEO görev süresi9.3yrs
CEO sahipliği0.9%
Yönetim ortalama görev süresi4.5yrs
Yönetim Kurulu ortalama görev süresi6.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Mar 24

Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 27

Cabaletta Bio: Do You Buy With The Insiders?

Summary Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA’s prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development. Strengths include promising pipeline updates, while risks remain around cash runway and clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Cabaletta Bio: Finding Optimism In Dire Straits

Summary Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches. With a market cap under $150 million, CABA's stock is a potential bargain if they achieve even partial success in their pipeline. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 10

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 22

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Summary I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company’s strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23. I rate Cabaletta a Buy for a 12-month outlook, assuming a position size of less than 1% of net portfolio assets, to adequately offset greater-than-normal risk. Read the full article on Seeking Alpha
Analiz Makalesi • Sep 04

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 28

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release. Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year. The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for. Read the full article on Seeking Alpha
Analiz Makalesi • May 22

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 31

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. By way of example, Cabaletta Bio...
Analiz Makalesi • Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Analiz Makalesi • Jun 04

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example...
Analiz Makalesi • Feb 11

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Analiz Makalesi • Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Jul 07

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO Tazminat Analizi

Steven Nichtberger'un ücretlendirmesi Cabaletta Bio'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$175m

Dec 31 2025US$2mUS$660k

-US$168m

Sep 30 2025n/an/a

-US$159m

Jun 30 2025n/an/a

-US$144m

Mar 31 2025n/an/a

-US$127m

Dec 31 2024US$8mUS$646k

-US$116m

Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Tazminat ve Piyasa: Steven 'ın toplam tazminatı ($USD 2.40M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.72M ).

Tazminat ve Kazançlar: Steven 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Steven Nichtberger (64 yo)

9.3yrs
Görev süresi
US$2,401,555
Tazminat

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 4.6m
David Chang
Chief Medical Officer6.9yrsUS$1.24m0.0054%
$ 28.8k
Gwendolyn Binder
President of Science & Technologyno dataUS$1.26m0.019%
$ 102.4k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Anup Marda
Chief Financial Officer7.3yrsUS$1.53mVeri yok
Qing Yuan
Chief Technology Officer1.9yrsVeri yokVeri yok
Samik Basu
Chief Scientific Officer4.5yrsVeri yokVeri yok
Michael Gerard
General Counsel & Secretary4.7yrsVeri yokVeri yok
Heather Harte-Hall
Chief Compliance Officer4.5yrsVeri yokVeri yok
Nicolette Sherman
Chief Human Resources Officer1.5yrsVeri yokVeri yok
Arun Das
Chief Business Officer4.3yrsVeri yokVeri yok
4.5yrs
Ortalama Görev Süresi
52yo
Ortalama Yaş

Deneyimli Yönetim: CABA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 4.6m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Richard Henriques
Independent Director7.3yrsUS$152.17k0%
$ 0
Carl June
Member of Scientific Advisory Board5.8yrsVeri yokVeri yok
Mark Simon
Independent Director7.6yrsUS$140.91k0.095%
$ 504.3k
Scott Brun
Independent Director4.9yrsUS$136.84k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board6.3yrsVeri yokVeri yok
Jay Siegel
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Georg Schett
Member of Scientific Advisory Board4.3yrsVeri yokVeri yok
Shawn Tomasello
Independent Director2.8yrsUS$119.17k0.014%
$ 74.3k
Catherine Bollard
Independent Director7.1yrsUS$145.57k0.0033%
$ 17.6k
6.3yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: CABA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/20 18:53
Gün Sonu Hisse Fiyatı2026/05/20 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cabaletta Bio, Inc. 15 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI